Vifor Fresenius Medical Care Renal Pharma

Clinical trials sponsored by Vifor Fresenius Medical Care Renal Pharma, explained in plain language.

Now part of Fresenius Medical Care AG FMS NYSE

Renal pharmaceutical company, a joint venture of Fresenius Medical Care and Vifor Pharma.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Trials to join now! 1 Not yet finished but already full! 1 Completed 2

Can a new drug tame vasculitis with fewer side effects?

Disease control Ongoing

This study tracks the safety of avacopan, a medication for ANCA-associated vasculitis, an autoimmune disease that causes blood vessel inflammation. Researchers will compare side effects like liver injury, heart problems, serious infections, and cancer in people taking avacopan ve…

Sponsor: Vifor Fresenius Medical Care Renal Pharma • Aim: Disease control

Last updated Jul 26, 2026 00:00 UTC

Vifor Fresenius Medical Care Renal Pharma

Can a new drug tame vasculitis with fewer side effects?